MRG003治疗晚期癌症的生存效益分析

Discussion of OS: In this study, although the OS data are not yet mature, there is a trend toward benefit in the MRG003 group as observed from the survival curves. Given that patients in the control group were allowed to cross over to receive MRG003 upon disease progression, sensitivity analyses showed that the MRG003 group could significantly reduce the risk of death. This is particularly noteworthy as the study included patients who had received up to five or more lines of prior therapy. Longer follow-up will be necessary to fully address the survival benefit of MRG003.